

**Structure-function Studies and
in silico Drug Discovery Targeting the Liver
Oncoprotein Gankyrin**

by
Iain Murchland, B. Biotech. (Hons)

A thesis submitted in fulfillment of the requirements
for the degree of Doctor of Philosophy



THE UNIVERSITY

of ADELAIDE

School of Molecular and Biomedical Science
Discipline of Biochemistry

August 2012

Table of Contents

Abstract	v
Declaration	vii
Acknowledgements	viii
Chapter 1 Introduction	1
1.1 Ankyrin repeat proteins	2
1.1.1 Structural properties of ankyrin repeat proteins	2
1.1.2 Functional diversity & conservation among ankyrin repeat proteins	7
1.2 Cell cycle regulation and cancer	11
1.2.1 Cell cycle overview	11
1.2.2 Key molecular regulators of the cell cycle	12
1.3 Gankyrin	15
1.3.1 Oncogenic properties of gankyrin	15
1.3.2 Normal cellular functions of gankyrin	15
1.3.3 Protein interaction partners of gankyrin	17
1.3.4 Mechanisms of gankyrin's oncogenic activity	22
1.4 Aims	24
1.5 A note on nomenclature	25
Chapter 2 Materials and Methods	27
2.1 Abbreviations	28
2.2 Materials	29
2.2.1 Chemicals and Reagents	29
2.2.2 Bacterial Strains	30
2.2.3 Plasmid Vectors	31
2.2.4 Oligonucleotides	32
2.2.5 Buffers, Solutions and media	33
2.2.6 Molecular weight standards	33
2.2.7 Antibodies	34
2.2.8 Kits	34
2.2.9 Miscellaneous materials	34
2.2.10 Software	35
2.3 Molecular Biology Techniques	35
2.3.1 Preparation of Plasmid DNA	35
2.3.2 Agarose gel electrophoresis	36
2.3.3 Polymerase Chain Reaction (PCR)	36
2.3.4 Restriction Enzyme Digest	36
2.3.5 DNA purification by agarose gel	36
2.3.6 DNA purification by solid phase adsorption	37
2.3.7 DNA ligation	37
2.3.8 Preparation of competent cells	37
2.3.9 Plasmid transformation	37

2.3.10 Clone screening by colony PCR	38
2.3.11 Cycle sequencing of DNA	38
2.3.12 Site-directed mutagenesis	38
2.3.13 LacZ reporter assays	39
2.4 Protein Chemistry Techniques	39
2.4.1 Expression of IPTG-inducible recombinant proteins	39
2.4.2 Preparation of bacterial lysates for protein purification	40
2.4.3 Purification of GST fusion proteins	40
2.4.4 Purification of poly-His tagged proteins	40
2.4.5 Concentration of protein samples	41
2.4.6 Buffer exchange by size exclusion chromatography	41
2.4.7 Buffer exchange by dialysis	41
2.4.8 Protein quantitation	41
2.4.9 Denaturing polyacrylamide gel electrophoresis	42
2.4.10 Western blot analysis	42
2.4.11 Protein labeling with FITC	43
2.4.12 Solid phase binding assay	43
2.4.13 GST pull-down experiments	44
2.5 NMR Spectroscopy Techniques	44
2.5.1 NMR sample preparation	44
2.5.2 NMR experiments	45
2.5.3 Ligand titration experiments	45
Chapter 3 In silico investigation of the gankyrin-pRb interaction	47
3.1 Introduction	47
3.1.1 Gankyrin and the Retinoblastoma protein	47
3.1.2 Protein-protein docking	51
3.2 Aims and Approaches	54
3.3 Results	57
3.3.1 Parallelisation of 3D-Dock	57
3.3.2 Protein-protein docking of gankyrin and pRb	59
3.3.3 Analysis of a novel model for the gankyrin-pRb interaction	64
3.3.4 Specificity of binding model	66
3.4 Discussion	70
Chapter 4 In vitro investigation of the gankyrin-pRb interaction	72
4.1 Introduction	73
4.1.1 Gankyrin-pRb binding model	73
4.2 Aims and Approaches	74
4.3 Results	75
4.3.1 Sub-cloning, expression and purification of gankyrin and mutants	75
4.3.2 Sub-cloning, expression and purification of pRbSP and mutants	76
4.3.3 Fluorescent labeling of gankyrin	79
4.3.4 Solid-phase gankyrin-pRb binding assay	80
4.3.5 Interrogation of gankyrin-pRb interaction by GST-pulldown	88
4.3.6 Semi-quantitative analysis of binding using a bacterial two-hybrid system	91

4.4 Discussion	93
Chapter 5 Small molecule inhibitors of gankyrin	96
5.1 Introduction	97
5.1.1 Protein-protein interactions as drug targets	97
5.1.2 In silico drug discovery	99
5.1.3 Gankyrin as a drug target	104
5.1.4 Characteristics of target site	105
5.2 Aims and Approaches	108
5.3 Results	109
5.3.1 In silico small molecule screening	109
5.3.2 NMR investigation of gankyrin and potential ligands	112
5.3.3 A positive control for G0-3 ligand binding	117
5.3.4 A test case for in silico discovery of ankyrin-repeat protein ligands	122
5.3.5 Comparison of scoring methods using the RNaseL test case	124
5.3.6 Comparing ligand burial of RNaseL ligands with a docking validation set	126
5.3.7 Can ligand burial analysis improve enrichment?	131
5.3.8 Burial analysis of gankyrin in silico docked compounds	135
5.4 Discussion	137
Chapter 6 Ankyrin repeat hydroxylation by FIH-1	142
6.1 Introduction	143
6.1.1 Factor Inhibiting HIF-1 (FIH-1)	143
6.1.2 Hydroxylation of ankyrin-repeat proteins	143
6.1.3 Specificity studies of the FIH/ankyrin interaction	144
6.2 Aims and Approaches	147
6.3 Results	147
6.3.1 Modelling of mNotch-1 and mNotch-4 peptides	147
6.3.2 Molecular dynamics of FIH/Notch peptide complexes	150
6.3.3 Binding and hydroxylation of gankyrin/S6C complex by FIH-1	155
6.4 Discussion	158
Chapter 7 Final Discussion	161
7.1 Gankyrin as a drug target	162
7.2 Molecular functions of gankyrin	164
7.3 Conclusion	169
References	170
Appendix A FTDock Modifications	181

Abstract

Gankyrin is an ankyrin repeat protein known for its oncogenic effects and its up-regulation in the early stages of almost all cases of hepatocellular carcinoma, as well as other cancers. It mediates its oncogenic effects via a series of protein-protein interactions with several key regulators of the cell cycle including, but not limited to, pRb, CDK4 and Mdm2. A better understanding of these interactions, including their structural details, would facilitate the development of novel therapeutics targeting gankyrin, as well as improving our understanding of gankyrin and the cell cycle control mechanisms it alters.

The nature of gankyrin's interaction with pRb is the subject of some dispute within the literature, including whether gankyrin is in a folded or unfolded state when interacting with pRb. Previous studies have identified that hydroxylation of ankyrin repeat proteins by FIH-1 requires substrate unfolding. Therefore, an investigation of the hydroxylation of gankyrin and other substrates demonstrates that gankyrin does not unfold when in complex with the C-terminal domain of the proteasomal S6 ATPase subunit. Molecular dynamics simulations of FIH-1 in complex with substrates derived from ankyrin repeats suggest that local sequence effects, as well as the tendency of the repeat to unfold, can determine whether or not an ankyrin repeat protein can be hydroxylated by FIH-1. Using hydroxylation to detect protein unfolding, this study provides further evidence that gankyrin interacts with pRb in a folded state, and via the use of *in silico* methods, proposes a structural model of the interaction. Mutations in gankyrin and pRb that are predicted to disrupt the interaction on the basis of the model do not result in altered binding when subjected to *in vitro* testing. An *in silico* screen to identify small molecules that can disrupt the gankyrin-CDK4 interaction was undertaken to identify lead compounds for the development of novel therapeutics for hepatocellular carcinoma and as a case study in the development of protein-protein interaction inhibitors. No lead molecules were identified, but the study provides evidence that the structural properties of gankyrin are amenable to the discovery of lead

molecules with affinities in at least the low micromolar range. By attempting to recapitulate the findings of an *in vitro* lead discovery screen targeting the ankyrin repeat domain of RNaseL using *in silico* techniques, the conclusion was drawn that such techniques, without further improvements, are unlikely to be successful in identifying small molecule ligands of ankyrin repeat proteins like gankyrin.

On the basis of this study, we can conclude that the discovery of small molecule inhibitors of gankyrin remains a valid and plausible objective, but that typical *in silico* techniques are unlikely to fulfil it. While the details of the interaction between gankyrin and pRb remain uncertain and thus inaccessible to drug design efforts, it can now be concluded with greater certainty that gankyrin participates in this interaction in its folded form. It therefore must do so via a mechanism that differs from other proteins containing an LXCXE motif.

Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Iain Murchland

Friday, September 7, 2012

Acknowledgements

First I would like to thank Associate Professor Grant Booker for the opportunity to undertake this PhD in his laboratory, for his tutelage during the course of the program, and his patience while the thesis was being written. In addition I thank the School of Molecular & Biomedical Sciences, and in particular the Discipline of Biochemistry, as well as my co-supervisor Associate Professor Simon Pyke for their roles in helping to make me the scientist I am today, and for providing a thoroughly enjoyable environment in which to work.

On the business end of things, I thank the Australian Government for providing my scholarship, eResearch SA for the use of their high-performance computational and visualization resources, and the School support staff for lightening the load a little with their administrative assistance and buffer and media preparations. I also thank Phil Clements and the School of Chemistry and Physics for maintenance of and access to the NMR spectrometer.

I am grateful for all the friends I have made in the Booker and Wallace labs over the years (in particular Huang-Hui Chen, Ethan Chen, Steven Polyak, Belinda Ng, Karina Martin, Lungisa Mayende, Tatiana Soares Da Costa, John Sharley, John Wallace, Briony Forbes, Carlie Delaine, Clair Alvino, Kerrie McNeil, Shee Chee Ong and Harinda Rajapaksha) for their willingness to help – whether that be with the serious matters of science, or the even more serious of matters of cake and coffee over morning tea, a laugh or two, or the odd philosophical and ideological discussion. Special mentions go to Phillippa Smith for a thoroughly enjoyable year working together and her contribution to the work on the gankyrin-CDK4 interaction and to Cvetan Stojkoski for his tutelage in all things computational and a great friendship. I also thank the Shearwin lab for the friendship and continued professional development they have given so generously over my peri-doctoral period. To my friends and collaborators in the Peet lab (Dan Peet, Sarah Linke, Sarah Wilkins and Rachel Hampton-Smith) – thanks for your infectious enthusiasm and for being so easy to work with, and of course for your contribution to this work via protein preparations and hydroxylation

assays (see in text for details). I am afraid one of the hazards of being a touch slow to submit is that there are too many people whose paths have crossed with mine to name them all individually here. I hope any of you reading this will accept my apologies and know that it in no way reflects the abundance or depth of my gratitude.

I also owe a debt of gratitude to my wider circle of friends and even more so my family. You have provided a constant source of support and encouragement, as well as one or two well-placed gibes to move me along the way. I fear I may not have completed this journey without your company, and for that I am very grateful.

One person without whom I know I would not have reached this point is my wife Rachel. To her I say this: your patience, understanding, support and encouragement throughout this process, and so many others that have become intertwined with it, has given me a glimpse of a love of almost incomprehensible depth. I can only hope that some day you can say something similar and that I am up to the task of matching the grace, humility and good humour with which you have supported me. But for now, a designation of “Dr Rachel” will have to suffice. And finally, a small thank you to young master Eli, who has brightened up these last months of writing no end, providing just the right amount of entertainment without causing too much trouble ... a trend he is most welcome to continue for as long as he likes!